source
- Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2BIt's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bris…Endpoints · 2mo ago↗ source
- Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCLRituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.onclive · 2mo ago↗ source
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.